J C Soria1, H K Gan2,3, S P Blagden4, R Plummer5, H T Arkenau6, M Ranson7, T R J Evans8, G Zalcman9, R Bahleda10, A Hollebecque10, C Lemech6, E Dean7, J Brown8, D Gibson11, V Peddareddigari11, S Murray11, N Nebot11, J Mazumdar11, L Swartz11, K R Auger11, R A Fleming11, R Singh11, M Millward12. 1. Drug Development Department at Gustave Roussy Cancer Campus, University Paris-Sud, Paris, France soria@igr.fr. 2. Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia. 3. School of Cancer Medicine, Latrobe University, Melbourne, Australia. 4. Imperial College, Hammersmith Hospital, London. 5. Northern Centre for Cancer Care, Newcastle. 6. Sarah Cannon Research Institute, London. 7. University of Manchester, Christie Hospital, Manchester. 8. University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK. 9. Early Phases Clinical Trials Unit at Caen University Hospital, Caen, France. 10. Drug Development Department at Gustave Roussy Cancer Campus, University Paris-Sud, Paris, France. 11. GlaxoSmithKline, Research Triangle Park, NC and Upper Providence, Collegeville, USA. 12. School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia.
Abstract
BACKGROUND: Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancer patients. PATIENTS AND METHODS: The dose of GSK2256098 was escalated, in cohorts of patients with advanced cancer, from 80 to 1500 mg, oral twice daily (BID), until the MTD was determined. Serial blood samples were obtained from all patients, and the PK was determined. Paired tumor biopsies were obtained in select patients, and the level of phospho-FAK (pFAK) was determined. RESULTS: Sixty-two patients (39 males, 23 females; median age 61 y.o., range 21-84) received GSK2256098. Dose-limiting toxicities of grade 2 proteinuria (1000 mg BID), grade 2 fatigue, nausea, vomiting (1250 mg BID), and grade 3 asthenia and grade 2 fatigue (1500 mg BID) were reported with the MTD identified as 1000 mg BID. The most frequent adverse events (AEs) were nausea (76%), diarrhea (65%), vomiting (58%), and decreased appetite (47%) with the majority of AEs being grades 1-2. The PK was generally dose proportional with a geometric mean elimination half-life range of 4-9 h. At the 750, 1000, and 1500 mg BID dose levels evaluated, the pFAK, Y397 autophosphorylation site, was reduced by ∼80% from baseline. Minor responses were observed in a patient with melanoma (-26%) and three patients with mesothelioma (-13%, -15%, and -17%). In the 29 patients with recurrent mesothelioma, the median progression-free survival was 12 weeks with 95% CI 9.1, 23.4 weeks (23.4 weeks merlin negative, n = 14; 11.4 weeks merlin positive, n = 9; 10.9 weeks merlin status unknown, n = 6). CONCLUSIONS: GSK2256098 has an acceptable safety profile, has evidence of target engagement at doses at or below the MTD, and has clinical activity in patients with mesothelioma, particularly those with merlin loss.
BACKGROUND:Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK2256098, in cancerpatients. PATIENTS AND METHODS: The dose of GSK2256098 was escalated, in cohorts of patients with advanced cancer, from 80 to 1500 mg, oral twice daily (BID), until the MTD was determined. Serial blood samples were obtained from all patients, and the PK was determined. Paired tumor biopsies were obtained in select patients, and the level of phospho-FAK (pFAK) was determined. RESULTS: Sixty-two patients (39 males, 23 females; median age 61 y.o., range 21-84) received GSK2256098. Dose-limiting toxicities of grade 2 proteinuria (1000 mg BID), grade 2 fatigue, nausea, vomiting (1250 mg BID), and grade 3 asthenia and grade 2 fatigue (1500 mg BID) were reported with the MTD identified as 1000 mg BID. The most frequent adverse events (AEs) were nausea (76%), diarrhea (65%), vomiting (58%), and decreased appetite (47%) with the majority of AEs being grades 1-2. The PK was generally dose proportional with a geometric mean elimination half-life range of 4-9 h. At the 750, 1000, and 1500 mg BID dose levels evaluated, the pFAK, Y397 autophosphorylation site, was reduced by ∼80% from baseline. Minor responses were observed in a patient with melanoma (-26%) and three patients with mesothelioma (-13%, -15%, and -17%). In the 29 patients with recurrent mesothelioma, the median progression-free survival was 12 weeks with 95% CI 9.1, 23.4 weeks (23.4 weeks merlin negative, n = 14; 11.4 weeks merlin positive, n = 9; 10.9 weeks merlin status unknown, n = 6). CONCLUSIONS:GSK2256098 has an acceptable safety profile, has evidence of target engagement at doses at or below the MTD, and has clinical activity in patients with mesothelioma, particularly those with merlin loss.
Authors: Friedrich Erhart; Matthias Hackl; Hannes Hahne; Johanna Buchroithner; Chen Meng; Simone Klingenbrunner; René Reitermaier; Katrin Fischhuber; Susanna Skalicky; Walter Berger; Sabine Spiegl-Kreinecker; Daniela Lötsch; Gerda Ricken; Bernhard Kuster; Adelheid Wöhrer; Georg Widhalm; Johannes Hainfellner; Thomas Felzmann; Alexander M Dohnal; Christine Marosi; Carmen Visus Journal: NPJ Vaccines Date: 2020-01-16 Impact factor: 7.344
Authors: Xiangmeng Wang; Po Yee Mak; Hong Mu; Wenjing Tao; Arvind Rao; Ravikumar Visweswaran; Vivian Ruvolo; Jonathan A Pachter; David T Weaver; Michael Andreeff; Bing Xu; Bing Z Carter Journal: Mol Cancer Ther Date: 2020-05-13 Impact factor: 6.261
Authors: John C Dawson; Alan Serrels; Dwayne G Stupack; David D Schlaepfer; Margaret C Frame Journal: Nat Rev Cancer Date: 2021-03-17 Impact factor: 60.716
Authors: Nicholas F Brown; Matthew Williams; Hendrik-Tobias Arkenau; Ronald A Fleming; Jerry Tolson; Li Yan; Jianping Zhang; Rajendra Singh; Kurt R Auger; Laurie Lenox; David Cox; Yvonne Lewis; Christophe Plisson; Graham Searle; Azeem Saleem; Sarah Blagden; Paul Mulholland Journal: Neuro Oncol Date: 2018-11-12 Impact factor: 12.300
Authors: Burles A Johnson; Mark Yarchoan; Valerie Lee; Daniel A Laheru; Elizabeth M Jaffee Journal: Clin Cancer Res Date: 2017-04-01 Impact factor: 12.531
Authors: E Giovannetti; P A Zucali; Y G Assaraf; N Funel; M Gemelli; M Stark; E Thunnissen; Z Hou; I B Muller; E A Struys; M Perrino; G Jansen; L H Matherly; G J Peters Journal: Ann Oncol Date: 2017-11-01 Impact factor: 32.976